Tessara Therapeutics (Melbourne, Australia) has the mission to protect, restore and rebuild the brain. Tessara manufactures RealBrain® mimetic human neural tissue with unique technology pushing the limits of approximation to actual human brain tissue in a dish. Tessara is converging innovation in neuroscience, biomaterials, industrial automation, artificial intelligence, and data analytics to commercialise their RealBrain® technology along two parallel pathways:
• Drug Discovery Platform (the only biologically true brain models that are suitable for high-throughput, high-content, industrial-scale analysis)
• Regenerative Medicine Platform (a world-first tissue replacement therapy for neurodegenerative and other neurological diseases)
The Company seeks Series A investors to help accelerate the development of the RealBrain® drug screening platform, position their game-changing models for market launch in 2023, and develop the regenerative medicine applications for eventual spinout
• Drug Discovery Platform (the only biologically true brain models that are suitable for high-throughput, high-content, industrial-scale analysis)
• Regenerative Medicine Platform (a world-first tissue replacement therapy for neurodegenerative and other neurological diseases)
The Company seeks Series A investors to help accelerate the development of the RealBrain® drug screening platform, position their game-changing models for market launch in 2023, and develop the regenerative medicine applications for eventual spinout
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
RealBrain® drug screening models (ArtiBrain™ model and ADBrain™ model)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
